PTH and osteoporosis: PTH (1-34), commonly known as teriparatide, holds the distinction of being the first anabolic agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of severe postmenopausal and glucocorticoid induced osteoporosis, due to its central role in the regulation of calcium and phosphorus metabolism [3].